Brief Description

Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure.
Target: sGC activator
Cinaciguat has potent preload- and afterload-reducing effects, increasing cardiac output. Cinaciguat causes potent and sustained fetal pulmonary vasodilation that is augmented in the presence of oxidized sGC and speculate that Cinaciguat may have therapeutic potential for severe neonatal pulmonary hypertension.

Solubility

10 mM in DMSO

Melting point

Boiling point

Density

Formula Weight:

Flash point

Storage conditions

Store at -20°C 2 years

Appearance:

White to off-white solid